 "Dr Reddy's Q1 net down 76% at Rs 154 cr")
Dr Reddy’s Laboratories was up nearly 3% to Rs 2,698 on the BSE in intra-day trade after the company said it has received Establishment Inspection Report (EIR) from the US health regulator for its Miryalaguda plant.
“We have received EIR from US Food and Drug Administration (US FDA) for its active pharmaceutical plant (API) at Miryalaguda indicating the successful closure of the agency's audit,” Dr Reddy’s Laboratories said in a statement.
The plant, which was inspected by USFDA from February 13-21’2017, had received Form 483 with three observations from USFDA.
“Miryalaguda plant supplies active ingredients for company’s
“We have received EIR from US Food and Drug Administration (US FDA) for its active pharmaceutical plant (API) at Miryalaguda indicating the successful closure of the agency's audit,” Dr Reddy’s Laboratories said in a statement.
The plant, which was inspected by USFDA from February 13-21’2017, had received Form 483 with three observations from USFDA.
“Miryalaguda plant supplies active ingredients for company’s
